The phase 3 trial involved over 800 candidates to assess ensifentrine when administered as a maintenance therapy to […]
Gilead pulls 2 cancer accelerated approvals as changing lymphoma landscape disrupts confirmatory trial aliu Mon, 01/24/2022 – 11:34
With omicron on the prowl, FDA extends inspection pause into February fkansteiner Mon, 01/24/2022 – 10:01
AbbVie’s Skyrizi nabs psoriatic arthritis nod, its second, shortly after Rinvoq fkansteiner Mon, 01/24/2022 – 09:03
BDSI readies liquid migraine medicine launch but stays away from ‘broad blast’ marketing campaign sharon.coey Mon, 01/24/2022 – […]
Robertson and Doshi are right that there will be no grand announcement of the end of the pandemic.1 […]
In their questioning of how to define the end of the pandemic, Robertson and Doshi state, surprisingly, that […]
AbstractFunctional neurological disorder (FND), previously regarded as a diagnosis of exclusion, is now a rule-in diagnosis with available […]
This editorial by Peter Doshi and colleagues (BMJ 2022;376:o102, doi:10.1136/bmj.o102) originally stated that the Medicines and Healthcare Products Regulatory Agency (MHRA) […]
Less selling, more science can best help doctors navigate complex new cancer treatments, report suggests nmissakian Sun, 01/23/2022 […]